February 2026 marked a significant chapter in the biotech sector, characterized by a series of high-profile acquisitions and strategic partnerships. While the number of mergers and acquisitions witnessed a minor decline, the impact of notable deals resonated throughout the industry. The momentum in biopharma dealings suggests a promising landscape as companies aim to expand their portfolios and enhance their therapeutic offerings.
Major Acquisitions Highlighted
A standout event was Gilead’s acquisition of Arcellx, a California-based biotech firm, for an impressive $7.8 billion. This strategic move, fueled by a remarkable 77% surge in Arcellx’s stock, centers around its lead candidate, an innovative CAR T-cell therapy for multiple myeloma named anito-cel. This acquisition underscores Gilead’s history of bold investments, reminiscent of its previous high-profile deals, such as the $21 billion purchase of Immunomedics.
In another significant development, Eli Lilly announced plans to acquire Orna Therapeutics for up to $2.4 billion. Specializing in RNA therapeutics, Orna is advancing a promising CAR-T therapy targeting CD19 for autoimmune diseases. This move reflects Lilly’s aggressive expansion strategy, with four deals signed since January, indicating a robust interest in innovative therapies.
British pharmaceutical giant GSK also made headlines by securing Quebec-based 35Pharma for $950 million. This acquisition includes HS235, a promising treatment for pulmonary hypertension, a condition affecting millions globally. GSK continues to solidify its position in the biotech arena, having made previous significant acquisitions to enhance its portfolio.
Licensing and Collaborative Agreements Flourish
Amidst these acquisitions, licensing deals also played a vital role in shaping the biotech landscape. GSK furthered its engagement with RNA therapeutics by collaborating with Nanjing-based Frontier Biotechnologies. This partnership aims to develop siRNA therapies, including a candidate currently in the investigational stage, signaling GSK’s commitment to advancing RNA technologies.
Genentech, a Roche subsidiary, partnered with SanegeneBio to support the latter’s RNAi program. This collaboration allows SanegeneBio to focus on early development, with Genentech stepping in for clinical advancements. The deal, valued at $200 million upfront, highlights the increasing interest in RNA interference technologies.
Madrigal Pharmaceuticals also made waves by teaming up with Ribocure Pharmaceuticals to develop six preclinical siRNA programs. This partnership enhances Madrigal’s innovative pipeline, particularly in the metabolic disease sector, where it has already gained recognition for its FDA-approved drug.
Antibodies Take Center Stage
February saw antibodies remain a key focus for dealmakers, with several significant collaborations emerging. CSL, an Australian pharmaceutical company, entered into an alliance with Memo Therapeutics to advance recombinant polyclonal IgG technology. This partnership is expected to yield up to CHF 265 million in milestone payments, emphasizing the growing importance of antibody-based therapies.
Additionally, CSL collaborated with Eli Lilly, transferring rights for its anti-interleukin-6 monoclonal antibody, clazakizumab. This phase 3 candidate aims to prevent heart-related issues in patients with end-stage kidney disease, marking CSL’s continued investment in antibody development.
Lilly also tapped into Jiangsu-based Innovent Biologics to enhance treatments for cancers and immune-related conditions. The partnership is structured to facilitate clinical advancements in China while Lilly oversees development outside the region.
Small Molecules Remain a Hot Commodity
The small molecule sector remains vibrant, with Gilead engaging Genhouse Bio to develop a synthetic lethal therapy targeting MAT2A. This partnership stands to provide Genhouse with $80 million upfront and the potential for significant milestone payments, further illustrating the allure of small molecules in therapeutic development.
Helsinn Healthcare and In Virtuo Laboratories also joined forces to discover novel small molecules, leveraging Helsinn’s extensive library against undisclosed therapeutic targets. The financial details of this collaboration remain undisclosed, but it represents a strategic effort to innovate in the small molecule space.
Moreover, Oxford-based Sitryx Therapeutics entered a licensing agreement with Boehringer Ingelheim for a preclinical program targeting immune diseases. This deal, valued at $500 million in milestone payments, underscores the persistent interest in small molecules addressing complex conditions.
The Role of AI in Biotech
The integration of artificial intelligence into drug discovery is gaining traction. Takeda and Iambic Therapeutics announced a partnership to leverage AI for developing small molecules targeting cancer and inflammatory conditions. This collaboration could yield over $1.7 billion for Iambic, signaling a shift toward data-driven approaches in biotech.
Similarly, Angelini Pharma teamed up with Quiver Biosciences to develop therapies targeting genetic epilepsies. This collaboration harnesses AI models to discover new drugs, showcasing the potential of technology to accelerate therapeutic development.
Conclusion
February 2026 proved to be a pivotal month for the biotech sector, highlighting a dynamic environment of acquisitions, strategic partnerships, and innovative collaborations. As companies continue to invest heavily in developing cutting-edge therapies, the landscape is poised for remarkable advancements. The interplay of mergers, licensing agreements, and technological integration will undoubtedly shape the future of biopharma, paving the way for novel treatment options.
- Noteworthy acquisitions included Gilead’s $7.8 billion purchase of Arcellx and Lilly’s planned $2.4 billion acquisition of Orna Therapeutics.
- GSK’s acquisition of 35Pharma for $950 million reinforces its commitment to innovative therapies in pulmonary hypertension.
-
Collaborations in RNA therapeutics and antibody development signal a growing trend in the industry.
-
The small molecule sector remains vibrant, with significant partnerships emerging to explore new therapeutic avenues.
-
The increasing integration of AI in biotech illustrates a transformative shift toward data-driven discovery methods.
Read more → www.labiotech.eu